Toggle light / dark theme

Convergent engagement of neural and computational sciences and technologies are reciprocally enabling rapid developments in current and near-future military and intelligence operations. In this podcast, Prof. James Giordano of Georgetown University will provide an overview of how these scientific and technological fields can be — and are being — leveraged for non-kinetic and kinetic what has become known as cognitive warfare; and will describe key issues in this rapidly evolving operational domain.

James Giordano PhD, is the Pellegrino Center Professor in the Departments of Neurology and Biochemistry; Chief of the Neuroethics Studies Program; Co-director of the Project in Brain Sciences and Global Health Law and Policy; and Chair of the Subprogram in Military Medical Ethics at Georgetown University Medical Center, Washington DC. Professor Giordano is Senior Bioethicist of the Defense Medical Ethics Center, and Adjunct Professor of Psychiatry at the Uniformed Services University of Health Sciences; Distinguished Stockdale Fellow in Science, Technology, and Ethics at the United States Naval Academy; Senior Science Advisory Fellow of the SMA Branch, Joint Staff, Pentagon; Non-resident Fellow of the Simon Center for the Military Ethic at the US Military Academy, West Point; Distinguished Visiting Professor of Biomedical Sciences, Health Promotions, and Ethics at the Coburg University of Applied Sciences, Coburg, GER; Chair Emeritus of the Neuroethics Project of the IEEE Brain Initiative; and serves as Director of the Institute for Biodefense Research, a federally funded Washington DC think tank dedicated to addressing emerging issues at the intersection of science, technology and national defense. He previously served as Donovan Group Senior Fellow, US Special Operations Command; member of the Neuroethics, Legal, and Social Issues Advisory Panel of the Defense Advanced Research Projects Agency (DARPA); and Task Leader of the Working Group on Dual-Use of the EU-Human Brain Project. Prof. Giordano is the author of over 350 peer-reviewed publications, 9 books and 50governmental reports on science, technology, and biosecurity, and is an elected member of the European Academy of Science and Arts, a Fellow of the Royal Society of Medicine (UK), and a Fulbright Professorial Fellow. A former US Naval officer, he was winged as an aerospace physiologist, and served with the US Navy and Marine Corps.

Originally released December 2023._ In today’s episode, host Luisa Rodriguez speaks to Nita Farahany — professor of law and philosophy at Duke Law School — about applications of cutting-edge neurotechnology.

They cover:
• How close we are to actual mind reading.
• How hacking neural interfaces could cure depression.
• How companies might use neural data in the workplace — like tracking how productive you are, or using your emotional states against you in negotiations.
• How close we are to being able to unlock our phones by singing a song in our heads.
• How neurodata has been used for interrogations, and even criminal prosecutions.
• The possibility of linking brains to the point where you could experience exactly the same thing as another person.
• Military applications of this tech, including the possibility of one soldier controlling swarms of drones with their mind.
• And plenty more.

In this episode:
• Luisa’s intro [00:00:00]
• Applications of new neurotechnology and security and surveillance [00:04:25]
• Controlling swarms of drones [00:12:34]
• Brain-to-brain communication [00:20:18]
• Identifying targets subconsciously [00:33:08]
• Neuroweapons [00:37:11]
• Neurodata and mental privacy [00:44:53]
• Neurodata in criminal cases [00:58:30]
• Effects in the workplace [01:05:45]
• Rapid advances [01:18:03]
• Regulation and cognitive rights [01:24:04]
• Brain-computer interfaces and cognitive enhancement [01:26:24]
• The risks of getting really deep into someone’s brain [01:41:52]
• Best-case and worst-case scenarios [01:49:00]
• Current work in this space [01:51:03]
• Watching kids grow up [01:57:03]

The 80,000 Hours Podcast features unusually in-depth conversations about the world’s most pressing problems and what you can do to solve them.

Learn more, read the summary and find the full transcript on the 80,000 Hours website:

Nita Farahany on the neurotechnology already being used to convict criminals and manipulate workers

A team of medical researchers and engineers at Google Research has developed a way to use the front-facing camera on a smartphone to monitor a patient’s heart rate. The team has published a paper on the technology on the arXiv preprint server.

Tracking a patient’s over time can reveal clues about their cardiovascular health. The most important measurement is resting heart rate (RHR)—people with an above-normal rate are at a higher risk of heart disease and/or stroke. Persistently high rates, the researchers note, can signal a serious problem.

Over the past several years, personal health device makers have developed wearable external heart monitors, such as necklaces or smartwatches. But these devices are expensive. The researchers have found a cheaper alternative—a deep-learning system that analyzes video from the front-facing camera of a smartphone. The system is called PHRM.

OSAKA — A Japanese research team is making progress on the development of a groundbreaking medication that may allow people to grow new teeth, with clinical trials set to begin in July 2024.

The tooth regrowth medicine is intended for people who lack a full set of adult teeth due to congenital factors. The team is aiming to have it ready for general use in 2030.

In prior animal experiments, the medicine prompted the growth of “third-generation” teeth following baby teeth and then permanent adult teeth.

S dream. I.

Photodynamic therapy uses a drug that is activated by light, called a photosensitizer or photosensitizing agent, to kill cancer cells. The light can come from a laser or other source, such as LEDs. Photodynamic therapy is also called PDT.

Photodynamic therapy is most often used as a local treatment, which means it treats a specific part of the body.

The study, “Endothelial TDP-43 Depletion Disrupts Core Blood-Brain Barrier Pathways in Neurodegeneration,” was published on March 14, 2025. The lead author, Omar Moustafa Fathy, an MD/Ph. D. candidate at the Center for Vascular Biology at UConn School of Medicine, conducted the research in the laboratory of senior author Dr. Patrick A. Murphy, associate professor and newly appointed interim director of the Center for Vascular Biology. The study was carried out in collaboration with Dr. Riqiang Yan, a leading expert in Alzheimer’s disease and neurodegeneration research.

This work provides a novel and significant exploration of how vascular dysfunction contributes to neurodegenerative diseases, exemplifying the powerful collaboration between the Center for Vascular Biology and the Department of Neuroscience. While clinical evidence has long suggested that blood-brain barrier (BBB) dysfunction plays a role in neurodegeneration, the specific contribution of endothelial cells remained unclear. The BBB serves as a critical protective barrier, shielding the brain from circulating factors that could cause inflammation and dysfunction. Though multiple cell types contribute to its function, endothelial cells—the inner lining of blood vessels—are its principal component.

“It is often said in the field that ‘we are only as old as our arteries’. Across diseases we are learning the importance of the endothelium. I had no doubt the same would be true in neurodegeneration, but seeing what these cells were doing was a critical first step,” says Murphy.

Omar, Murphy, and their team tackled a key challenge: endothelial cells are rare and difficult to isolate from tissues, making it even harder to analyze the molecular pathways involved in neurodegeneration.

To overcome this, they developed an innovative approach to enrich these cells from frozen tissues stored in a large NIH-sponsored biobank. They then applied inCITE-seq, a cutting-edge method that enables direct measurement of protein-level signaling responses in single cells—marking its first-ever use in human tissues.

This breakthrough led to a striking discovery: endothelial cells from three different neurodegenerative diseases—Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD)—shared fundamental similarities that set them apart from the endothelium in healthy aging. A key finding was the depletion of TDP-43, an RNA-binding protein genetically linked to ALS-FTD and commonly disrupted in AD. Until now, research has focused primarily on neurons, but this study highlights a previously unrecognized dysfunction in endothelial cells.

“It’s easy to think of blood vessels as passive pipelines, but our findings challenge that view,” says Omar. “Across multiple neurodegenerative diseases, we see strikingly similar vascular changes, suggesting that the vasculature isn’t just collateral damage—it’s actively shaping disease progression. Recognizing these commonalities opens the door to new therapeutic possibilities that target the vasculature itself.”